Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGM-148 Single Ascending Dose Study in Healthy Participants
NCT07843368Phase 1Recruiting
- Sponsor
- Tangram Therapeutics
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing TGM-148 with Placebo (2 arms). Primary endpoint: Frequency and severity of adverse events at 16 weeks. Started Oct 2026; status: recruiting.
02
Drugs
ETX-148
Beyond the preview
Go deeper on NCT07843368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843368.